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members to follow up with their physicians; patient reminder
postcards; educational materials and newsletters; Diabetic
Control Network—a 12-month patient self educated program;
vision provider contract requirement included performance guar-
antees to improve eye exam rates; mailings to providers a list of
their diabetic patients who had not received the necessary ser-
vices; provider and patient gift certiﬁcate incentive programs;
providers on site education, and updated ADA diabetes stan-
dards of care. Results of baseline measurement and 12-month
post intervention re-measurement were compared. RESULTS: A
signiﬁcant improvement in all selected quality indicators were
found: HbA1c poorly controlled rate was 48.42%, a decreased
of 19.46% (p < 0.001) from baseline; eye exam rates was
48.66%, an increased of 10.70% (p < 0.05) from baseline; LDL-
C level <130mg/dL was 55.96%, an increased of 10.46% (p <
0.05) from baseline, LDL-C level <100mg/dL was 31.87%; and
nephropathy monitoring was 53.28%, an increased of 8.51% (p
< 0.05) from baseline. CONCLUSIONS: Results of this study
demonstrated substantial improvement in all selected diabetes
indicators. Although results of our interventions are encourag-
ing, expanded effort is still needed to further improve rates of
diabetic management among Medicaid members.
PDB43
SHOULD WE LOOK FOR A NEW APPROACH IN DIABETES
MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE
STRATEGY IN THE POLISH SETTING?
Sieradzki J1, Kinalska I2, Niewada M3, Faluta T4, Czech M4, Latek M5,
Wilkins A4, Szczepanski M4, Pachocki R4
1Medical College, Jagiellonian University in Krakow, Krakow, Poland;
2Medical University in Bialystok, Bialystok, Poland; 3Medical University
of Warsaw, Warsaw, Poland; 4Servier Poland, Warsaw, Poland;
5Warsaw School of Economics, Warszawa, Mazowieckie, Poland
The high prevalence of undiagnosed diabetes and the large pro-
portion of individuals with complications at diagnosis (50%
according to UKPDS 33) argue for screening for Type-2 diabetes.
The NHANES study conﬁrms the substantially higher risk of
death, lower survival, and lower life expectancy of diabetic
adults compared with non-diabetic adults. A UK Prospective
Diabetes Study shows that intensive blood-glucose control can
reduce risk of any diabetes-related death and any diabetes-
related endpoints. OBJECTIVE: The aim of the study was to
assess cost-effectiveness of active screening for DM and intensive
blood-glucose control in comparison with conventional treat-
ment in patients with DM II in the Polish population.
METHODS: The Markov model of DM progression to stimu-
late lifetime and related health care cost was constructed. Demo-
graphic characteristics of a stimulated cohort as well as cost of
health care were based on a CODIP study population. Costs
were analysed from a societal viewpoint and included only direct
medical costs. Costs of active searching for DM and the distrib-
ution of people on diagnostic pathways came from an epidemi-
ological Screen-Pol 2 study. The age-dependant risk of death and
transition probabilities between disease stages were obtained
from the NHANES study. The effectiveness of active blood-
glucose control was derived from the UKPDS 33. RESULTS: In
the long term (20 years), a strategy based on active blood-glucose
control could bring an additional 0.4 life years saved (LYS) per
patient. An additional LYS costs €457. If active blood-glucose
control is preceded by the active screening for DM, this strategy
could bring 0.71 LYS per patient. The cost-effectiveness ratio
amounts to €10,863/LYS. CONCLUSIONS: The most effective
strategy in DM management is based on an early detection
program and active blood-glucose control. The cost-effectiveness
ratio for active glucose control is extremely low.
PDB44
USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR
PREVENTION IN PRIMARY CARE PATIENTS WITH 
DIABETES MELLITUS
Sicras A1, Navarro R1, Xavier F1, Ruíz R1, Rejas J2, Fernández J2
1Badalona Servicios Asistenciales, SA, Badalona, Barcelona, Spain;
2Pﬁzer Spain, Alcobendas/Madrid, Spain
OBJECTIVE: Use of acetyl salicylic acid (ASA) for primary pre-
vention (PP) and secondary prevention (SP) of cardiovascular
disease (CVD) in adult diabetic patients is highly recommended.
This study was conducted in order to determine the use of ASA
and to assess the achievement of therapeutic targets in diabetic
patients. METHODS: This is a retrospective and observational
study. Sample consisted of patients >18 years with diabetes 
mellitus followed in four primary care centers. Measurements
included demographics, use of ASA and/or anticoagulant drugs,
co-morbidities, clinical parameters and proportion of patient at
therapeutic target (TT). Descriptive statistics, chi-square test and
logistic regression model were used for signiﬁcance. RESULTS:
A total of 4140 diabetic patients were analyzed, 79.1% 
(95% conﬁdence interval: 77.7%–80.5%) in PP and 20.9%
(18.2%–23.7%) in SP. Mean age was 64.1 (13.8) years, and
49.3% of patient were men (PP: 46.3; SP: 60.7; p = 0.000). ASA
were prescribed on a routine basis in 29.2% (27.8%–30.6%);
20.8% (19.4%–22.2%) in PP and 60.8% (57.6%–64.0%) in SP.
Proportion of patient at TT was 48.0% for hypertensives and
59.8% for hypercholesterolemics, being these the most frequent
antecedents observed in SP. Older patients [OR = 1.01
(1.00–1.02); p = 0.011], number of cardiovascular-risk factors
[OR = 1.14 (CI: 1.03–1.27); p = 0.013], LDL-c TT [OR = 1.42
(1.06–1.88); p = 0.017], and a poor metabolic control of gly-
cated hemoglobin [OR = 1.51 (1.22–1.89); p = 0.000] were
covariates associated to the use of ASS in PP. CONCLUSIONS:
Treatment with ASA is underused for PP in patients with dia-
betes mellitus in Primary Care. Achievement of TT should be
improved.
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OBJECTIVE: This study determined the predictors of antidia-
betes medication adherence and health care costs in adults with
Type-2 diabetes mellitus in the United States. METHODS: The
2000 Medical Expenditure Panel survey was used for the analy-
ses. The population for analyses was identiﬁed using ICD-9 CM
codes for Type-2 diabetes. The predictor variables were demo-
graphics variables, self-reported health status (EuroQol score),
and health services utilization variables. The dependent variables
in this analysis were diabetes medication possession (number of
diabetes medication reﬁlls) and annual health care costs. Multi-
variate weighted analysis was performed to identify signiﬁcant
predictors of medication utilization and health care costs.
RESULTS: There were 11.7 million patients with reported Type-
2 diabetes in the United States in 2000, based on survey extrap-
olation. On an average, there were ten diabetes drug reﬁlls
reported by patients. The average annual health care costs for
these patients were $7466, while the mean EuroQol summary
score was 48%. Increase in the health status summary score
(EuroQol) by 10% was associated with a slight (1%) decrease
in diabetes drug reﬁlls (p < 0.05). An additional diabetes related
emergency visit or an inpatient visit was associated with a nearly
50% increase compared to the average diabetes medication uti-
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lization (p < 0.01). An increase in the EuroQol score by 10%
was signiﬁcantly associated with decrease in annual health care
costs by 4.5% (p < 0.05). Each diabetes drug reﬁll was signiﬁ-
cantly associated with increase in the average health care costs
by 3.7% (p < 0.001), while each diabetes related inpatient visit
was associated with a 117% increase in average health care costs
(p < 0.001). CONCLUSIONS: This study showed signiﬁcant
associations between diabetes related utilization, health status
and diabetes medication adherence. Medication utilization was
further signiﬁcantly associated with health care costs. The study
ﬁndings highlight the need for maintaining improved health
status, and promoting cost-effective drug therapy in Type-2 
diabetes.
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and antidiabetic medication use in Germany. METHODS: Data
for this study were obtained from the German Disease Ana-
lyzer—Mediplus database. All patients who were identiﬁed with
type-2 diabetes between January 1, 2004 and December 31,
2004, were at least 20 years of age, and received at least one
HbA1c test between April 1, 2004 and December 31, 2004 were
included in the analysis (N = 5,135). Medication use was exam-
ined for the 90 days prior to the individual’s most recent HbA1c
test. RESULTS: Among those patients who were treated with
antidiabetic medication (61.93%), individuals were most com-
monly prescribed metformin monotherapy (33.55%), sulfony-
lurea monotherapy (18.18%), oral combination therapy
(17.68%), insulin monotherapy (16.92%), or insulin plus oral
therapy (7.13%). Over half of all patients diagnosed with type-
2 diabetes (52.74%) did not obtain a recommended range of
glycemic control of 6.5% or below. Comparing patients who
were within the recommended range of glycemic control to those
above the targeted range revealed no signiﬁcant differences in
mean age, sex, or comorbidities reported in 2004. In contrast,
there were signiﬁcant differences in the percentage of patients
who obtained the recommended range of glycemic control based
on antidiabetic medication prescribed (p < 0.0001). Patients
treated with insulin combination therapy or insulin monother-
apy were least likely to be within the targeted range of HbA1c
(22.91% and 26.58%, respectively), while only 31.85% of those
treated with oral combination therapy were within the targeted
range. CONCLUSIONS: Over half of patients diagnosed with
type-2 diabetes do not achieve the targeted range of glycemic
control. For a majority of patients, alternative therapy regimens
seem necessary to achieve good glycemic control.
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OBJECTIVE: In patients with type-2 diabetes (PwT2D) sufﬁ-
cient blood glucose control, also at an early stage, often cannot
be reached by using oral antidiabetic drugs (OAD) alone so that
the administration of insulin is necessary. Frequently, insulin
therapy is initiated too late, which is mostly due to the patients’
aversion to insulin. The aim of this survey was to investigate the
inﬂuence of knowledge about insulin and the willingness to start
using insulin treatment (WUI) in PwT2D on HbA1c not ade-
quately controlled on OAD alone. METHODS: Study materials
were sent out nation-wide to general practitioners by mail. The
patient questionnaire covered the following topics: WUI;
patients’ reported well-being; perceived seriousness of T2D; per-
ceived susceptibility to diabetic complications; expectations
regarding beneﬁcial and adverse effects of insulin; perceived
incompatibility with daily routine. A 10-point rating scale (1 =
totally disagree / 10 = totally agree) was used to document
patient assessments. The assessments were analyzed descrip-
tively. RESULTS: Out of 729 patients, 448 were treated with
OAD only. In total, 222 had low WUI (1–5 points = group1/G1);
217 had high WUI (6–10 points = group2/G2); not answered n
= 9. A high percentage of patients indicated that they were aware
of the seriousness of their T2D (G1 = 83%; G2 = 93% agree-
ment). Yet, the majority of the patients did not agree that they
had a severe stage of T2D (G1 = 79%; G2 = 73%). Patients with
lower WUI showed less knowledge regarding insulin. HbA1c
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OBJECTIVE: Given that control of blood glucose improves
long-term outcomes for patients diagnosed with type-2 diabetes,
the objective of this study is to examine levels of glycemic control
W
IT
HD
RA
W
N
